| __timestamp | PTC Therapeutics, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 79838000 | 179279000 |
| Thursday, January 1, 2015 | 121816000 | 186359000 |
| Friday, January 1, 2016 | 117633000 | 171785000 |
| Sunday, January 1, 2017 | 4577000 | 208136000 |
| Monday, January 1, 2018 | 12670000 | 198405000 |
| Tuesday, January 1, 2019 | 12135000 | 224169000 |
| Wednesday, January 1, 2020 | 18942000 | 245044000 |
| Friday, January 1, 2021 | 32328000 | 252314000 |
| Saturday, January 1, 2022 | 44678000 | 268225000 |
| Sunday, January 1, 2023 | 65486000 | 304629000 |
| Monday, January 1, 2024 | 324203000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for PTC Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Taro consistently outpaced PTC in cost of revenue, with figures peaking at approximately $324 million in 2023, marking a 81% increase from 2014. In contrast, PTC's cost of revenue showed more volatility, starting at around $80 million in 2014, dipping to a low of $4.6 million in 2017, and recovering to $65 million by 2023. This fluctuation highlights PTC's dynamic operational strategies. Notably, data for 2024 is incomplete, emphasizing the need for continuous monitoring. As the pharmaceutical landscape shifts, these insights offer a window into the financial health and strategic priorities of these industry leaders.
Analyzing Cost of Revenue: Takeda Pharmaceutical Company Limited and Taro Pharmaceutical Industries Ltd.
BioMarin Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and PTC Therapeutics, Inc.'s Expenses
Jazz Pharmaceuticals plc vs PTC Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Alkermes plc vs Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: PTC Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Mesoblast Limited
PTC Therapeutics, Inc. vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
PTC Therapeutics, Inc. vs Evotec SE: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Wave Life Sciences Ltd. vs Taro Pharmaceutical Industries Ltd.
Cost of Revenue Comparison: Taro Pharmaceutical Industries Ltd. vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Taro Pharmaceutical Industries Ltd. vs BioCryst Pharmaceuticals, Inc.